Autolus' Obe-cel Wins FDA RMAT Designation for Lupus, Accelerating Path to Market
AUTL sits 83% above its 52-week low of $1.175.
Summary
Autolus announced FDA granted RMAT designation to obe-cel for systemic lupus erythematosus and lupus nephritis. RMAT provides expedited development and review, including potential rolling BLA submission and priority review, which could shorten time to market. This follows strong Q2 2026 AUCATZYL revenue of $45.7M and raised guidance, but obe-cel represents a major pipeline expansion into autoimmune disease. The designation is based on Phase 1b CARLYSLE data, and the next data update is submitted for ACR in Q4 2026. LUMINA, the pivotal Phase 2 in refractory lupus nephritis, is enrolling in five countries with data expected in 2028. For a $562M market cap company, this regulatory milestone validates the autoimmune strategy and could attract partnership interest.
At the time of this announcement, AUTL was trading at $2.15 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $561.6M. The 52-week trading range was $1.18 to $2.58. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.